Status:
COMPLETED
Intravitreal Ozurdex After Pars Plana Vitrectomy for Proliferative Diabetic Retinopathy
Lead Sponsor:
Anders Kvanta
Conditions:
Proliferative Diabetic Retinopathy
Eligibility:
All Genders
12+ years
Phase:
PHASE2
Brief Summary
To evaluate if intravitreal Ozurdex can reduce the incidence of recurrent vitreous hemorrhage after primary pars plana vitrectomy (PPV) in patients with proliferative diabetic retinopathy (PDRP).
Detailed Description
To perform a randomized, controlled, study on patients that undergo PPV for vitreous hemorrhage secondary to PDRP. Half of the patients will receive an intravitreal Ozurdex implant immediately after s...
Eligibility Criteria
Inclusion
- Patients with vitreous hemorrhage undergoing PPV for PDRP
Exclusion
- Previous PPV
- Vitreous hemorrhage of non-PDRP origin
Key Trial Info
Start Date :
November 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2016
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT01478737
Start Date
November 1 2011
End Date
April 1 2016
Last Update
January 30 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
St. Erik Eye Hospital
Stockholm, NonUS, Sweden, 11282